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Background:  Morinda citrifolia Linn (noni), as a “pain killer”, has been used as a traditional 
medicine by Polynesians for over 2000 years. It was reported to have a broad range of 
therapeutic effects including analgesic and anti-inflammation. The in-vitro and in vivo anti-
inflammatory and analgesic properties of noni juice (NJ) suggest that NJ may be a useful 
adjunctive treatment for osteoarthritis (OA).  In this pilot study we explored whether NJ 
improves the symptoms and Quality of Life (QoL) for adults with OA. We also sought to 
evaluate the tolerability and safety of NJ for patients with OA in a primary care setting.  
 
Methods:  This was an open label three-month intervention pilot study.  Data were collected by 
pre/post intervention survey and laboratory testing. Inclusion criteria were: adults of both sexes 
aged 40 to 75, with a diagnosis of OA on the hip or knee by x-ray examination provided by their 
primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz 
of NJ a day for 90 days.   
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Results:  Of the 64 questions measuring different aspects of QoL asked on the pre/post survey, 
49 (77%) had significant pre/post mean scale differences as measured by independent t-test. The 
OA patients reported being significantly more satisfied with their current health conditions 
including mobility, walking and bending, hand, finger, and arm functions, household tasks, 
social activity, arthritis pain, work ability, level of tension, and mood. The study participants 
were also more positive about their future health and reported taking less over-the-counter (OTC) 
pain relievers. Pre/post laboratory testing including: lipid panel, liver and kidney functions were 
in the normal ranges. High Sensitive C Reactive Protein (hsCRP), an inflammatory biomarker, 
was reduced by 10% after the intervention.  
 
Conclusion:   As a nutritional supplement, NJ demonstrated a potential therapeutic effect and 
improved the symptoms and the QoL for adults with OA. A larger, double blinded, and placebo 
controlled clinical trial study is needed to confirm these benefits. NJ has the potential to become 
an adjunctive therapy for OA patients.   
 
Clinical trial registration number:  NCT01070264. 
 
Key words:        Morinda citrifolia (noni), Noni juice (NJ), Osteoarthritis, Quality of   




Approximately 10% of people in the U.S. have OA, making it the most common form of arthritis 
and one of the most prevalent chronic diseases in western countries.  For people older than 75 the 
estimated prevalence of OA rises to between 70 - 90% [1].  
         While the etiology of OA is multi-factorial, the condition results from the gradual 
degeneration of joint cartilage. Joint cartilage normally cushions the bones in a joint and if 
damaged causes bone overgrowth and fragmentation of the cartilage which can lead to 
inflammation, pain and functional impairment. As a result it is not surprising that OA is a leading 
cause of disability and that between 10 to 30 % of those affected with OA suffer from significant 
pain and disability [2-6]. 
       Disease modifying treatments that halt the progression of OA remain elusive and as a 
result current management focuses on reducing symptoms [7]. These include interventions such 
as weight loss, exercise, analgesics, steroid joint injections, joint replacement and medications 
[8]. Non-steroid anti-inflammatory drugs [NSAIDs] are one type of medication though widely 
used for symptoms, have a significant side effect profile that compromises their benefits. While 
selective cyclooxygenase (Cox-2) inhibitors provide symptom relief with reduced GI side 
effects, an associated increase in the risk of cardiovascular disease led to several of these drugs 
being withdrawn from the market [9]. Due to a favorable safety profile many consider 
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acetaminophen as drug of choice for OA; however, acetaminophen predominately affects pain 
and may have only a modest benefit on improving function and relieving stiffness [10].  Faced 
with these challenges, many patients and health providers turn to alternative methods [11]. One 
viable alternative may be the complementary therapy of NJ made from Morinda citrifolia (noni) 
fruits [12].  
       Several research studies support the rationale for the traditional use of NJ for treating 
inflammatory and analgesic disorders [11, 13].  For decades, Polynesians have used noni for pain 
and to reduce inflammation [14].  The specie Morinda citrifolia L. [noni] belongs to the genus 
Morinda and the family Rubiaceae.  Morinda includes about 80 species, of which noni is 
considered the “queen” [15]. Studies examining noni reported that the noni fruit possesses 
analgesic and tranquilizing activities [16]. An alcohol extract of noni fruit puree showed an 
analgesic and anti-inflammatory effect by inhibiting MMP-9 release from human monocytes 
after stimulation with lipopolysaccharides (LPS) and this effect was comparable to hydro-
cortisone. The authors claimed that preparations of noni fruits are effective in decreasing pain 
and joint destruction caused by arthritis (17). Younis and his colleagues tested the analgesic and 
sedative effects of noni extract and found “a significant, dose-related, central analgesic activity 
in mice” and that “the analgesic efficacy of the noni extract was about 75% as strong as 
morphine, yet non-addictive and side effect free [18]”.  Research comparing the analgesic effect 
of NJ to aspirin using hot-plate and twist assays in mice also supports NJ as a potentially 
effective treatment for OA [19].  
       Additionally, an anti-inflammatory effect of NJ was observed in acute liver injury models 
induced by CCl4 in female SD rats [20]. Other research revealed anti-oxidative activity that 
scavenges reactive oxygen species (ROS) and quenches lipid peroxides (LPO) in smokers [21].  
Of particular interest in terms of NJ’s potential as a therapeutic natural product for OA, is the 
finding the NJ is a partial Cox-2 inhibitor in vitro with an inhibitory effect about 40% of the 
effect of celexcoxib [22].   
       These research findings coupled with its traditional use as a treatment for pain suggest 
that NJ might be an effective therapeutic nutritional supplement for OA patients. The goal of this 
study was to conduct a preliminary exploration of NJ’s impact on the symptoms and QoL of OA 
patients and at the same time to examine its tolerability and safety as a complimentary 
therapeutic nutritional agent for OA. 
 
Methods and Materials 
This study was a 12-week open label pilot intervention study for individuals with OA to explore 
the potential benefit of NJ for symptoms associated with OA. Research participants were 
recruited consecutively and enrolled into the study until a targeted sample size of approximately 
100 was reached.  Pre/post intervention assessment was used to examine efficacy. The inclusion 
criteria entailed: adults aged 40 to 75 of both sexes with X-ray diagnosis of OA of the hip or 
knee who were not taking prescription medicine for arthritis and were willing to drink 3 oz of NJ 
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daily for 90 days. The diagnostic criteria were deliberately set to mimic the real life clinical 
setting in which NJ would most likely be used---a primary care physician diagnosis of OA for 
those experiencing symptoms of OA proved by x-ray examination. Adults appearing to meet the 
study’s eligibility criteria were interviewed by an experienced clinical coordinator to confirm 
eligibility and to ensure that potential study participants were willing to complete all of the study 
measures including blood draws. Informed consent was obtained from the participants once it 
was ascertained that they met the enrollment criteria and were willing to participate. 
       To help ensure the intake of a daily dose of 3 oz of NJ, all enrolled study participants 
were asked to drink 1 oz in the morning before breakfast, 1 oz before lunch, and 1 oz before 
bedtime. Study participants picked up their one-month supply of NJ at the time of enrollment, 
and again at the end of the first and then second month of the intervention. A 20 ml blood sample 
for laboratory testing was drawn at enrollment and at the last visit. To confirm compliance with 
the treatment protocol, the remaining NJ from the previous month’s supply was measured and 
recorded. At the time of follow up, the study coordinator asked the study participants if they 
were experiencing any new problems or symptoms that precluded their receiving the next NJ 
allotment.  
       The clinical coordinator attempted to contact by phone anyone who failed to show up for 
a follow up appointment. If a research participant failed to respond after 3 contacts or more than 
30 days or missed 3 scheduled appointments they were dropped from the study. The NJ used in 
this study was Tahitian Noni® juice donated by Morinda Holding Inc. The study was approved 
by the University of Illinois-Chicago, College of Medicine at Rockford’s Institutional Review 
Board.  
       At enrollment as baseline and then again at the end of the last visit, two validated 
instruments were used to collect pre/post intervention study data on self-reported pain from QoL 
associated with OA. The Arthritis Impact Measurement Scales [AIMS 2] were used to measure 
self-reported pain in the study participants [23]. The Short Form-36 Version 2 [SF-36 V2] form 
was used for the evaluation of QoL [24].  Both the AIMS 2 and the SF-36 V2 are validated 
instruments [25]. Reliability and validity of the AIMS 2 have been well documented in arthritis 
patients. The SF-36 V2 is both a multipurpose survey of general health status as well as a QoL 
measure.  
        Some modifications, however, were made to the instruments. Due to the overlap of some 
items on the AIMS 2 and the SF-36 V2, we combined the two forms into one questionnaire.  The 
AIMS 2 questionnaire includes 78 items used to establish severity of an individual’s clinical 
status; these were included in the combined questionnaire. This instrument also contains 
subscales for pain, stiffness, and function. The SF-36 questionnaire consists of several self-
efficacy questions used to assess QoL. The QoL questions asked study participants to appraise 
their current level of function and satisfaction, compared to what they perceive to be their ideal. 
This assessment also asked study participants to express their ability to perform daily activities 
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across multiple domains including: physical, social, cognitive functioning role activities, and 
emotional well-being. 
       In addition to the two validated measures, another questionnaire was used to collect data 
on patient characteristics such as age, gender, race, social status, and height and weight to 
calculate body mass index [BMI], disease related characteristics [location of symptoms, duration 
of symptoms, family history] and co-morbidities. Of these, BMI and co-morbidities were 
monitored throughout the intervention study. 
 
Statistical analysis    
A power analysis was calculated for a two-tailed test of significance using a t-test for a medium 
effect size, alpha was set at <0.05 and beta at .80.  This analysis yielded that a sample size of 70 
would be sufficient to detect possible significant differences pre/post intervention and a decision 
was made to recruit approximately 100 study participants to assure a minimum of 70 subjects 
when accounting for possible attrition. 
       Several statistical tests were used to determine if the NJ intervention yielded a significant 
impact on the self-reported QoL measures for each study participant. Basic t-test analysis was 
performed [26-27] with the differences in the primary outcomes [pain and function] measured 
before and after the intervention study based on the intention to treat. The safety of NJ was 
evaluated based on the compliance of the study participants and laboratory test performed on the 
blood samples.   
 
Results  
One hundred and one adults with OA enrolled in the study and 82 [81%] completed the 
intervention study. While several of those completing the intervention study complained about 
the unpleasant taste of NJ, no one reported a side effect that precluded them from completing the 
intervention study. Of the 19 who did not complete the intervention study, one moved from the 
area, one was hospitalized for reasons unrelated to NJ and one was dropped from the intervention 
study because she reported to the study coordinator that her primary care physician detected 
asymptomatic hyperkalemia on a routine blood test. The remaining original study participants 
either did not respond to multiple attempts to reach them or they rescheduled appointments but 
failed to appear. 
  Table 1 displays the demographic characteristics of the study participants who completed 
the intervention study. Almost 75% [74.4%] of the participants completing the intervention study 
were female, half [50.0%] were obese [BMI > 30], 32.9% were overweight, and the vast majority 
[93.9%] were Caucasian. A little over half of the completing intervention study participants were 
partnered [59.0%], 62.2% did not graduate from college and 61.2% lived in households with 
incomes > $40,000. Those who did not complete the study did not differ significantly from the 
study group who finished the intervention study.  
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Table 1. Demographic characteristic of study participants completing the 3-month trial 
 
 Variables n % 
Gender Male 21 25.6 
Female 61 74.4 
 
BMI Normal 14 17.1 
Overweight 27 32.9 
Obese 41 50.0 
 
Race Caucasian 77 93.9 
African American 5 6.1 
 
Marital Status Partnered 49 59.0 
Not Partnered 34 41.0 
 
Years of Formal 
Education 
< College Education 51 62.2 
College Graduate 31 37.8 
 
Household Income < $40,000 31 38.8 
> $40,000 49 61.2 
Note: Age 62.1 ± 8.1 [mean ± SD]. Classification of BMI: normal [BMI < 24.9], over weight [BMI=25.0 to 29.9, 
obese [BMI=30.0 or higher].  
 
       Of the 64 questions related to QoL, 49 [77%] had significant pre/post differences in the 
mean as measured by an independent t-test. All the differences that achieved statistical 
significance favored post intervention study improvement on the QoL measures. Table 2 
summarizes the significant pre/post changes in the QoL measures for the body movement and 
function measures. All of the movement and function questions were asked in terms of the past 
month.   
       Table 3 displays the significant pre/post changes in the QoL measures for study 
participants on the duration and severity of arthritis pain, psychological state measures of tension 
and mood and satisfaction with QoL on multiple dimensions. All questions were asked in terms 
of the past month. The results indicated that both the duration and the severity of pain were 
reduced post intervention study and after the consumption of NJ over a three month time frame. 
Regarding the psychological state measures of tension and mood the results also revealed that 
both the level of tension experienced by OA patients participating in this intervention study as 
well as the mood of the study participants improved. The results measuring the significant 
pre/post differences in level of satisfaction on multiple dimensions indicated that there were 
statistically significant pre/post positive differences in OA patient satisfaction with mobility, 
walking and bending, hand and finger functions, arm function, self-care, household tasks, social 
activity, arthritis pain, work, level of tension, and mood.      
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       The impact that the study participant’s OA had on multiple dimensions was also assessed 
pre/post during the NJ clinical intervention study. The question was posed in terms of: How 
much of your problem in each area of health was due to your arthritis?  The significant results 
are displayed in Table 4. For the dimensions of walking and bending, arthritis pain, work, level 
of tension, and mood the impact of OA was significantly lessened. 
 
Table 2.   Pre/post assessment of QoL measures on movement and function 
These questions were asked in terms of the past month.   
Pre-trial 
[mean ± SD] 
Post-trial 




Scale 1 [no days]-5 [all 
days] 
 
How often were you out of the house for at 







How often were you able to do errands in 







How often did someone have to assist you 







How often were you in bed or chair for 







Walking and bending 
Scale 1 [no days]-5 [all 
days] 
 
Did you have trouble doing vigorous 
activities such as running, lifting heavy 










Did you have trouble either walking several 















Did you have trouble either walking one 







Arm function  
Scale 1 [no days]-5 [all 
days] 
Could you easily put on a pullover sweater?  4.73 0.69 4.840.46 < 0.05 
Could you easily comb or brush your hair?  4.74 0.73 4.900.29 < 0.05 
Could you easily reach shelves that were 





Did you need help with a bath or shower?  1.27 0.71 1.120.55 < 0.01 
Did you need help to get dressed?  1.210 .58 1.060.28 0.000 
Household tasks 
Scale 1[never]-5[always] 
If you had the necessary transportation, 
could you go shopping for groceries 






Support from Friends 
and Family  
Scale 1[never]-5[always] 
Did you feel that your family or friends 
understood the effects of your arthritis? 
3.501.03 3.781.12 
< 0.05 
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Table 3.   Pre/post assessment of arthritis pain, psychological state and satisfaction measures 
All questions were asked in terms of the past month.   
            Pain measures 
Pre-trial 
[mean ± SD] 
Post-trial 




arthritis pain  Scale 
1 [no days] - 5 [all 
days] 
 








How often did you have pain in two or more joints 







How often did your morning stiffness last more 















Severity of arthritis 
pain  Scale 1 
[none] - 5 [severe] 
How would you describe the arthritis pain you 







Psychological state measures scale 1 [never] - 5 [always] 
Level of tension 
 
How often have you felt tense or high strung?  2.961.01 2.510.85 < 0.01 
How often have you been bothered by nervousness 











How often have you felt calm and peaceful?  3.350.79 3.660.77 < 0.01 
Mood 
 
How often have you enjoyed the things you do?  3.820.79 4.040.69 < 0.01 




How often did you feel that nothing turned out the 







How often did you feel that others would be better 







How often did you feel so down in the dumps that 







Satisfaction measures scale 1[very dissatisfied] - 5 [very satisfied] 
Mobility level  [example: do errands]  3.141.48 3.931.22 0.000 
Walking and bending [example: climb stairs]  2.331.28 3.371.33 0.000 
Hand and finger function  [example: tie a bow]  3.881.26 4.430.93 < 0.01 
Arm function [example: comb hair]  4.211.17 4.450.94 < 0.05 
Household tasks [example: housework]  3.521.35 4.111.12 < 0.05 
Social activity [example: visit friends]  4.081.24 4.341.11 0.000 
Arthritis pain [example: joint pain]  2.111.15 3.141.23 0.000 
Work  [example: reduced hours]  3.411.32 4.181.15 0.000 
Level of tension [example: felt tense]  3.261.27 4.021.05 0.000 
Mood [example: down in the dumps]  3.631.12 4.131.03 0.000 
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Table 4.   Pre/post assessment of impact of arthritis on area of health. 
How much of your problem in each area of health was due to your 
arthritis?  This question was asked in terms of the past month.   
Scale 1 [due entirely to my arthritis] – 6 [not a problem for me]  
     Pre-trial     







Walking And Bending  [example: climb stairs]  2.381.35 2.781.53 < 0.05 
Arthritis Pain  [example: joint pain]  1.951.02 2.501.37 0.000 
Work  [example: reduced hours]  3.981.82 4.691.67 0.000 
Level of tension  [example: felt tense]  4.111.58 4.731.45 < 0.01 




Table 5 presents data on study participants’ pre/post assessments of their current and 
future health. Study participants indicated that they felt more positive about their current and 
future health after the 3-month NJ intervention study. Study participants reported that 
satisfaction with health improved,  the degree to which health problems were attributed to OA 
lessened, an assessment of self health in comparison to peer’s improved and the frequency to 
taking medication for OA decreased post intervention study.  
 
Table 5.   Pre/post assessment of current and future health 
 
Pre-trial 






How satisfied are you with your health now?  Scale 1 [very 







How much of your problem with your health now is due to your 








Considering all the ways that your arthritis affects you, how well are 
you doing compared to other people your age?  Scale 1 [very poorly] 










How often have you had to take medication for your arthritis? Scale 1 






   < 0.001 
 
Patients were also assessed by pre/post intervention study laboratory tests [see Table 6]. 
With the exception of a very modest increase in creatinine levels, all other markers tested 
remained unchanged 
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Table 6.   Pre/post laboratory results 





Kidney function Urea nitrogen 15.44.1 14.85.5 > 0.05 
Creatinine 0.910.16 0.970.19 < 0.05 
BUN/Creatinine ratio 16.9±25.6 15.3±5.7 > 0.05 
Liver function Total  protein 7.11.6 6.90.4 > 0.05 
Albumin 4.00.33 4.00.4 > 0.05 
Bilirubin total 0.820.51 0.770.26 < 0.05 
Bilirubin direct 0.140.1 0.120.06 > 0.05 
ALP 74.230.0 73.529.3 > 0.05 
AST 26.911.7 26.111.0 > 0.05 
ALT 24.79.5 22.98.2 > 0.05 
Lipoprotein profile Total cholesterol 191.935.5 197.934.0 > 0.05 
Triglyceride 120.171.6 121.880.9 > 0.05 
Inflammatory 
marker 
Hs-C-reactive protein 4.94.99 4.23.6 > 0.05 




No ideal agent exists for the treatment of OA and while a number of OTC and prescription 
medications are available, many patients turn to nutraceuticals for managing their OA. In a 2009 
study, over 40% of those surveyed used an alternative OA treatment [28]. Despite their wide use, 
many in the scientific community remain skeptical about alternative agents since there is often 
little evidence to support their use. The study reported on here explored if NJ, one type of widely 
used nutraceutical, improved the symptoms and QoL of adults with a diagnosis OA. The findings 
of this 12-week pilot study intervention suggested that NJ may be an effective treatment for OA.  
Our results revealed that study group scores improved in multiple dimensions including pain 
symptoms, QoL measures, functional activity and psychological well being. An added benefit 
was that research participants reported taking other supplemental OTC medications for OA less 
frequently. 
       The improvement in pain scores and function found in this pilot study was not surprising 
given that NJ has demonstrated effectiveness in both lab and animal models as a dual Cox-1 and 
Cox-2 inhibitor and pain reliever. More interesting were the concomitant improvements in QoL, 
psychological well being, satisfaction with personal health, and having a more positive outlook 
on life.  While this may be a secondary result of reduced pain symptoms and improved function, 
a wide range of in vitro studies up-to-date indicate that NJ has biological activity that might yield 
additional clinical benefit beyond its ability to relieve pain and improve function. These include 
findings that demonstrate antioxidant activity [29], antimicrobial activity [30], xanthene oxidase 
inhibition [31], and an inhibitory effect on lipoprotein lipase activity [32]. Recently Deng and 
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colleagues demonstrated significant binding affinity of noni extract to the gamma-aminobutyric 
acid A [GABAa] inhibitory neurotransmitter receptor which provides a possible biological 
mechanism for the stress reducing benefits seen in this intervention study [22]. However, while 
these and other studies demonstrate a biologic rationale for NJ, the importance of this pilot study 
is that it is one of the few human studies that provide evidence of NJ’s potential benefit in a 
clinical setting [33]. 
       In addition to evaluating NJ’s benefits as a nutraceutical, this pilot study sought to 
evaluate its tolerability and safety. In general, previous reports have indicated that NJ is safe and 
that adverse effects consist mainly of benign gastrointestinal complaints occurring in less than 
5% of cases [34]. Our findings suggest a similar safe profile for NJ with a high percentage 
[>80%] adhering to and completing the study protocol. The most commonly reported complaint 
was of its unpleasant taste and no one reported any rashes or allergic reactions. The issue of 
whether NJ causes hepatotoxicity is debated in the literatures [35-40]. However, in this pilot 
intervention study no evidence of liver toxicity was seen either clinically or in lab testing.   
       Hyperkalemia associated with NJ has also been reported previously [41], and one 
individual enrolled in the intervention study reported asymptomatic hyperkalemia and was 
dropped from the intervention study. Subsequent retesting revealed that the potassium level 
returned to normal after one week. The potassium content in NJ is consistent with many 
commonly consumed fruit juices and is significantly less than the amount found in higher 
potassium foods such as bananas. However, our experience and the published case reports of 
hyperkalemia associated with NJ suggests that NJ should be used cautiously in patients at risk 
for hyperkalemia and that serum potassium may need to be monitored in individuals using NJ on 
a consistent basis.    
       There are several important limitations to this study.  First, the study was not a 
randomized trial with a control group and enrolled only a relatively small number of subjects. 
However, the study was not intended to be a definitive study but instead was planned as an 
exploratory pilot intervention study to see if NJ merited further investigation. The study findings 
appear sufficient to suggest that NJ may be a promising alternative to traditional treatment for 
OA, meriting further investigation.   
       A second limitation was that only English speaking patients who had knee or hip pain 
attributed to OA by their family physician were included in the study.  Third, only people over 
40 years of age were included.  By excluding younger and non-English speaking patients, our 
findings cannot be generalized to a broad spectrum of patients or those with other types of 
musculoskeletal symptoms. Fourth, since significantly fewer men than women enrolled in the 
intervention study, generalizing the findings to men should be done with caution. Fifth, we chose 
not to use the diagnostic criteria of the American College of Rheumatology for OA of the hip 
and knee, relying instead on confirmation from x-ray examination provided by a primary care 
physician that the person enrolling in the study had OA. We believe, however, that our inclusion 
criteria were more consistent with how NJ is used and were appropriate for a pilot intervention 
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study. A sixth limitation centers on patients who were lost to follow up. We recognize that it is 
possible that some of those individuals might have experienced side effects. However, we 
believe it unlikely that any unreported side-effects represent a serious adverse reaction. 
Throughout the intervention study, the coordinator requested that anyone experiencing problems 
contact her and no one other than the individual with asymptomatic hyperkalemia did so. In 
several attempts to contact those who dropped out, no one responded with a concern related to 
NJ. Finally NJ [Tahitain Noni® juice] the product used in this intervention study may be unique 
and other noni products may not yield similar benefit. Another limitation is that the findings rely 
primarily on self-reported data and as such is subject to bias especially in an open label trial. 
However, this study used validated reporting scales and in a disease such as OA where the goal 
is to improve symptoms self report is a key marker for determining the efficacy of a treatment. 
While open label, the authors believe the strength of the findings coupled with its relative safety 
suggest that NJ merits further investigation in a blinded study.  
 
Conclusion  
The results from this 12-week pilot intervention study suggest that NJ is potential, safe, and 
effective agent that may be able to reduce the symptoms of OA and help improve QoL. While 
other studies have demonstrated the pharmacologic effects of NJ in vitro and in animal models, 
few human studies have been conducted to support NJ benefits in a clinical setting. This pilot 
study suggests the need for further rigorous examination to confirm the benefits seen here and to 
ascertain the safety profile of NJ in a larger sample. 
 
List of abbreviations:  
NJ=Noni juice; QoL=Quality of Life; OA=Osteoarthritis; BMI=Body Mass Index; AIMS 
2=Arthritis Impact Measurement Scales; SF-36 V2=Short Form-36 Version 2; NSAIDs=Non-
steroid anti-inflammatory drugs; hsCRP=High Sensitive C Reactive Protein;  ROS=Reactive 
Oxygen Species; LPO=lipid peroxides; GI= Gastrointestinal; Cox=Cyclooxy-genase; SD 
rats=Sprague Dawley rats; GABAa=gamma-aminobutyric acid A; ALP=alkaline phosphatase; 
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